A functional SUMO-interacting motif in the transactivation domain of c-Myb regulates its myeloid transforming ability

Oncogene

Volumn 30, Issue 2, 2011, Pages 212-222

  Saether T ^a   Pattabiraman, D R ^b   Alm Kristiansen, A H ^a   Vogt Kielland, L T ^a   Gonda, T J ^b   Gabrielsen, O S ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

c Myb; hematopoiesis; myeloid; SUMO; SUMO interacting motif; transformation

Indexed keywords

PROTEIN C MYB; SUMO 2 PROTEIN; SUMO 3 PROTEIN;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL LINE; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; HEMATOPOIETIC CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF; TRANSACTIVATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CERCOPITHECUS AETHIOPS; CONSENSUS SEQUENCE; COS CELLS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; MYELOID CELLS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MYB; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS;

EID: 78651390345     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.397     Document Type: Article

References (47)

1. Alm-Kristiansen AH, Saether T, Matre V, Gilfillan S, Dahle O, Gabrielsen OS. (2008). FLASH acts as a co-activator of the transcription factor c-Myb and localizes to active RNA polymerase II foci. Oncogene 27: 4644-4656.
2. Andersson KB, Kowenz-Leutz E, Brendeford EM, Tygsett AH, Leutz A, Gabrielsen OS. (2003). Phosphorylation-dependent down-regulation of c-Myb DNA binding is abrogated by a point mutation in the v-myb oncogene. J Biol Chem 278: 3816-3824.
3. Bies J, Markus J, Wolff L. (2002). Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity. J Biol Chem 277: 8999-9009.
4. Brown AL, Wilkinson CR, Waterman SR, Kok CH, Salerno DG, Diakiw SM et al. (2006). Genetic regulators of myelopoiesis and leukemic signaling identified by gene profiling and linear modeling. J Leukoc Biol 80: 433-447.
5. Burk O, Mink S, Ringwald M, Klempnauer KH. (1993). Synergistic activation of the chicken mim-1 gene by v-myb and C/EBP transcription factors. EMBO J 12: 2027-2038.
6. Chen RH, Lipsick JS. (1993). Differential transcriptional activation by v-myb and c-myb in animal cells and Saccharomyces cerevisiae. Mol Cell Biol 13: 4423-4431.
7. Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela JM, Dik WA et al. (2007). The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 110: 1251-1261.
8. Dahle O, Andersen TO, Nordgard O, Matre V, Del Sal G, Gabrielsen OS. (2003). Transactivation properties of c-Myb are critically dependent on two SUMO-1 acceptor sites that are conjugated in a PIASy enhanced manner. Eur J Biochem 270: 1338-1348.
9. Dai P, Akimaru H, Tanaka Y, Hou DX, Yasukawa T, Kanei-Ishii C et al. (1996). CBP as a transcriptional coactivator of c-Myb. Genes Dev 10: 528-540.
10. Dash AB, Orrico FC, Ness SA. (1996). The EVES motif mediates both intermolecular and intramolecular regulation of c-Myb. Genes Dev 10: 1858-1869.
11. Dubendorff JW, Whittaker LJ, Eltman JT, Lipsick JS. (1992). Carboxy-terminal elements of c-Myb negatively regulate transcrip-tional activation in cis and in trans. Genes Dev 6: 2524-2535.
12. Gabrielsen OS, Sentenac A, Fromageot P. (1991). Specific DNA binding by c-Myb: evidence for a double helix-turn-helix-related motif. Science 253: 1140-1143.
13. Geiss-Friedlander R, Melchior F. (2007). Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 8: 947-956.
14. Gill G. (2005). Something about SUMO inhibits transcription. Curr Opin Genet Dev 15: 536-541.
15. Gonda TJ, Buckmaster C, Ramsay RG. (1989). Activation of c-myb by carboxy-terminal truncation: relationship to transformation of murine haemopoietic cells in vitro. EMBO J 8: 1777-1783.
16. Hannich JT, Lewis A, Kroetz MB, Li SJ, Heide H, Emili A et al. (2005). Defining the SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae. J Biol Chem 280: 4102-4110.
17. Hay RT. (2005). SUMO: a history of modification. Mol Cell 18: 1-12.
18. Hecker CM, Rabiller M, Haglund K, Bayer P, Dikic I. (2006). Specification of SUMO1- and SUMO2-interacting motifs. J Biol Chem 281: 16117-16127.
19. Hoeller D, Hecker CM, Dikic I. (2006). Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 6: 776-788.
20. Hu YL, Ramsay RG, Kanei-Ishii C, Ishii S, Gonda TJ. (1991). Transformation by carboxyl-deleted Myb reflects increased trans-activating capacity and disruption of a negative regulatory domain. Oncogene 6: 1549-1553.
21. Jin S, Zhao H, Yi Y, Nakata Y, Kalota A, Gewirtz AM. (2010). c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J Clin Invest 120: 593-606.
22. Karafiat V, Dvorakova M, Pajer P, Kralova J, Horejsi Z, Cermak V et al. (2001). The leucine zipper region of Myb oncoprotein regulates the commitment of hematopoietic progenitors. Blood 98: 3668-3676.
23. Kasper LH, Boussouar F, Ney PA, Jackson CW, Rehg J, Van Deursen JM et al. (2002). A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis. Nature 419: 738-743.
24. Kerscher O, Felberbaum R, Hochstrasser M. (2006). Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 22: 159-180.
25. Knipscheer P, Flotho A, Klug H, Olsen JV, Van Dijk WJ, Fish A et al. (2008). Ubc9 sumoylation regulates SUMO target discrimination. Mol Cell 31: 371-382.
26. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F et al. (2007). Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 39: 593-595.
27. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L et al. (2008). Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10: 547-555.
28. Lane T, Ibanez C, Garcia A, Graf T, Lipsick J. (1990). Transformation by v-myb correlates with trans-activation of gene expression. Mol Cell Biol 10: 2591-2598.
29. Lin DY, Huang YS, Jeng JC, Kuo HY, Chang CC, Chao TT et al. (2006). Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell 24: 341-354.
30. McCormack MP, Gonda TJ. (2000). Novel murine myeloid cell lines that exhibit a differentiation switch in response to IL-3 or GM-CSF, or to different constitutively active mutants of the GM-CSF receptor beta subunit. Blood 95: 120-127.
31. Minty A, Dumont X, Kaghad M, Caput D. (2000). Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem 275: 36316-36323.
32. Molvaersmyr AK, Saether T, Gilfillan S, Lorenzo PI, Kvaloy H, Matre V et al. (2010). A SUMO-regulated activation function controls synergy of c-Myb through a repressor-activator switch leading to differential p300 recruitment. Nucleic Acids Res 38: 4970-4984.
33. Murati A, Gervais C, Carbuccia N, Finetti P, Cervera N, Adelaide J et al. (2009). Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia 23: 85-94.
34. Ness SA, Kowenz-Leutz E, Casini T, Graf T, Leutz A. (1993). Myb and NF-M: combinatorial activators of myeloid genes in hetero-logous cell types. Genes Dev 7: 749-759.
35. Oelgeschlager M, Janknecht R, Krieg J, Schreek S, Luscher B. (1996). Interaction of the co-activator CBP with Myb proteins: effects on Myb-specific transactivation and on the cooperativity with NF-M. EMBO J 15: 2771-2780.
36. Pattabiraman DR, Sun J, Dowhan DH, Ishii S, Gonda TJ. (2009). Mutations in multiple domains of c-Myb disrupt interaction with CBP/p300 and abrogate myeloid transforming ability. Mol Cancer Res 7: 1477-1486.
37. Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. (2009). Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 106: 18740-18744.
38. Ramsay RG, Gonda TJ. (2008). MYB function in normal and cancer cells. Nat Rev Cancer 8: 523-534.
39. Reverter D, Lima CD. (2005). Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature 435: 687-692.
40. Saether T, Berge T, Ledsaak M, Matre V, Alm-Kristiansen AH, Dahle O et al. (2007). The chromatin remodeling factor Mi-2alpha acts as a novel co-activator for human c-Myb. J Biol Chem 282: 13994-14005.
41. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. (2006). The mechanisms of PML-nuclear body formation. Mol Cell 24: 331-339.
42. Song J, Durrin LK, Wilkinson TA, Krontiris TG, Chen Y. (2004). Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci USA 101: 14373-14378.
43. Song J, Zhang Z, Hu W, Chen Y. (2005). Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif: a reversal of the bound orientation. J Biol Chem 280: 40122-40129.
44. Sramko M, Markus J, Kabat J, Wolff L, Bies J. (2006). Stress-induced inactivation of the c-Myb transcription factor through conjugation of SUMO-2/3 proteins. J Biol Chem 281: 40065-40075.
45. Takahashi H, Hatakeyama S, Saitoh H, Nakayama KI. (2005). Noncovalent SUMO-1 binding activity of thymine DNA glycosy-lase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein. J Biol Chem 280: 5611-5621.
46. Tatham MH, Kim S, Jaffray E, Song J, Chen Y, Hay RT. (2005). Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection. Nat Struct Mol Biol 12: 67-74.
47. Vorbrueggen G, Kalkbrenner F, Guehmann S, Moelling K. (1994). The carboxy terminus of human c-myb protein stimulates activated transcription in trans. Nucleic Acids Res 22: 2466-2475.